Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis
about
Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis
description
im Mai 2019 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 23 May 2019
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в травні 2019
@uk
name
Pazopanib has equivalent anti- ...... ell carcinoma: a meta-analysis
@en
Pazopanib has equivalent anti- ...... ell carcinoma: a meta-analysis
@nl
type
label
Pazopanib has equivalent anti- ...... ell carcinoma: a meta-analysis
@en
Pazopanib has equivalent anti- ...... ell carcinoma: a meta-analysis
@nl
prefLabel
Pazopanib has equivalent anti- ...... ell carcinoma: a meta-analysis
@en
Pazopanib has equivalent anti- ...... ell carcinoma: a meta-analysis
@nl
P2093
P921
P1433
P1476
Pazopanib has equivalent anti- ...... ell carcinoma: a meta-analysis
@en
P2093
P356
10.1186/S12885-019-5704-3
P407
P577
2019-05-23T00:00:00Z